Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984225 | 0.82 | HDAC4 (0.49) | HDAC4EPHX2PDE7AORAI1KDM4E | |
| SCHEMBL27687662 | 0.77 | HTT (0.42) | P2RX7KAT6AMEN1KMT2ACA12 | |
| SCHEMBL3924833 | 0.72 | HDAC3 (0.42) | FFAR4KDM4EMEN1KMT2ACA12 | |
| SCHEMBL5077894 | 0.72 | MAPT (0.46) | KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL5079244 | 0.70 | SLC6A4 (0.52) | EPHX2 | |
| SCHEMBL3924576 | 0.70 | HDAC4 (0.44) | HDAC4 | |
| SCHEMBL14263259 | 0.69 | ORAI1 (0.46) | HDAC4EPHX2ORAI1KDM4EMEN1 | |
| SCHEMBL2783267 | 0.69 | NOTUM (0.41) | HDAC4FFAR4P2RX7NOTUM | |
| SCHEMBL5075891 | 0.67 | PDE7A (0.38) | HDAC4FFAR4P2RX7NOTUMEPHX2 | |
| SCHEMBL6583082 | 0.67 | MAOA (0.50) | MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| EP-1482925-B1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL]-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1482925-A1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL!-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | Schering AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232824-A1 | Non-steroidal progesting | SCHERING AG (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075915-A1 | 5-}2-HYDROXY-3-`1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPYL!-PROPIONYLAMINO}- PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| EP-1344776-A1 | 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders | Schering Aktiengesellschaft (DE) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232824-A1 | Non-steroidal progesting | PGR, NR5A1, GPER1 | HDAC4 1718/4885FFAR4 295/4885P2RX7 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.